#1 Clinical Trials Search in Europe

Briquilimab

Briquilimab is an innovative drug currently being studied in various clinical trials for its potential in treating chronic urticaria, allergic asthma, and sickle cell disease. These trials aim to evaluate the safety, efficacy, and long-term effects of briquilimab in patients who have not responded well to standard treatments. The research spans different phases and designs, from open-label studies to randomized, placebo-controlled trials, providing valuable insights into this promising medication.

Table of Contents

What is Briquilimab?

Briquilimab, also known as JSP191, is a new drug currently being studied for its potential to treat various immune-related conditions[1][2][3][4]. It is an antibody, which is a type of protein that helps your immune system recognize and fight off harmful substances in your body. Briquilimab is still in the experimental stage, meaning it’s being tested in clinical trials to determine its effectiveness and safety before it can be approved for general use.

What Conditions Does Briquilimab Treat?

Based on the ongoing clinical trials, Briquilimab is being investigated for several conditions:

  • Chronic Inducible Urticaria (CIndU): This includes conditions like Cold Urticaria (ColdU) and Symptomatic Dermographism (SD). These are types of hives that are triggered by specific stimuli, such as cold temperatures or pressure on the skin[1].
  • Chronic Spontaneous Urticaria (CSU): This is a condition where hives appear for no apparent reason and last for more than six weeks[2].
  • Allergic Asthma: A type of asthma triggered by allergens like pollen, dust mites, or pet dander[3].
  • Sickle Cell Disease (SCD): A genetic blood disorder that affects the shape of red blood cells, causing various complications[4].

How Does Briquilimab Work?

While the exact mechanism of action is still being studied, Briquilimab appears to target specific components of the immune system. In conditions like chronic urticaria and allergic asthma, it may help reduce the overactive immune response that causes symptoms[1][2][3]. In the case of sickle cell disease, it’s being used as part of a treatment regimen to prepare patients for stem cell transplants, which can potentially cure the disease[4].

How is Briquilimab Administered?

Briquilimab is typically administered through subcutaneous injection, which means it’s injected just under the skin[1][2][3]. In some cases, particularly for sickle cell disease treatment, it may be given intravenously (directly into a vein)[4]. The dosage and frequency of administration can vary depending on the condition being treated and the specific clinical trial protocol.

Current Clinical Trials

Several clinical trials are currently underway to evaluate Briquilimab:

  • A Phase 1b/2a trial for Chronic Inducible Urticaria, testing single doses of 40mg, 120mg, and 180mg[1].
  • A Phase 1b/2a trial for Chronic Spontaneous Urticaria, using various doses in a three-part escalation study[2].
  • A proof-of-concept study for Allergic Asthma, using a single dose to evaluate its effects on asthmatic responses to allergens[3].
  • A Phase I/II study for Sickle Cell Disease, where Briquilimab is part of a combination therapy to prepare patients for stem cell transplants[4].

Safety and Side Effects

As Briquilimab is still in clinical trials, its full safety profile is not yet established. The ongoing studies are closely monitoring for any adverse events (side effects). Common measures being tracked include:

  • Incidence and severity of treatment-emergent adverse events (TEAEs)
  • Serious adverse events (SAEs)
  • Changes in laboratory values and vital signs

It’s important to note that all participants in these trials are closely monitored by healthcare professionals to ensure their safety[1][2][3][4].

Future Prospects

The ongoing clinical trials aim to determine the effectiveness and safety of Briquilimab for various conditions. If successful, this drug could provide new treatment options for patients with chronic urticaria, allergic asthma, and potentially improve outcomes for those undergoing stem cell transplants for sickle cell disease. However, it’s important to remember that drug development is a long process, and it may be some time before Briquilimab becomes widely available, if approved[1][2][3][4].

Condition Trial Phase Key Features Primary Outcomes
Chronic Urticaria Phase 2 Open-label extension study Long-term safety and clinical activity
Chronic Inducible Urticaria Phase 1b/2a Dose escalation, open-label Safety, tolerability, preliminary efficacy
Chronic Spontaneous Urticaria Phase 1b/2a Dose escalation, partially blinded Safety, tolerability, preliminary efficacy
Allergic Asthma Not specified Double-blind, placebo-controlled Safety, effect on allergen-induced responses
Sickle Cell Disease Phase 1/2 Non-myeloablative haploidentical transplantation Engraftment success, absence of severe GVHD

FAQ

  • What is Briquilimab? Briquilimab is an investigational drug being studied for its potential to treat various conditions, including chronic urticaria (hives), allergic asthma, and sickle cell disease. It is administered through subcutaneous injection and is being tested in different doses and treatment schedules.
  • What conditions are being studied with Briquilimab? Clinical trials are currently investigating Briquilimab for chronic spontaneous urticaria, chronic inducible urticaria, allergic asthma, and sickle cell disease. These studies aim to determine its effectiveness in patients who haven't responded well to standard treatments.
  • How is Briquilimab being tested in clinical trials? Briquilimab is being tested in various trial designs, including open-label studies, dose-escalation trials, and randomized, placebo-controlled studies. These trials evaluate different aspects such as safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy in the target patient populations.
  • What are the main outcomes being measured in these trials? The primary outcomes typically include safety and tolerability, measured by the incidence and severity of adverse events. Efficacy outcomes vary by condition but may include changes in symptom scores, quality of life measures, and specific disease-related markers. Some trials also look at long-term effects and the drug's impact on the immune system.
  • How long do these clinical trials last? The duration of the trials varies, but many last for several months to over a year. For example, some studies follow patients for up to 48 weeks, while others, like the sickle cell disease trial, have a follow-up period of up to 5 years to assess long-term outcomes and safety.

Ongoing Clinical Trials on Briquilimab

  • Study on Long-Term Safety of Briquilimab for Patients with Chronic Urticaria

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effects of Briquilimab in Adults with Chronic Spontaneous Urticaria Unresponsive to Antihistamines

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Briquilimab for Adults with Chronic Inducible Urticaria Unresponsive to H1-Antihistamines

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Chronic Urticaria: A condition characterized by recurring hives (itchy, raised welts on the skin) that last for more than six weeks. It can be spontaneous or induced by specific triggers.
  • Chronic Spontaneous Urticaria (CSU): A form of chronic urticaria where hives appear without any known external trigger.
  • Chronic Inducible Urticaria (CIndU): A type of chronic urticaria where hives are triggered by specific stimuli, such as cold (Cold Urticaria) or friction (Symptomatic Dermographism).
  • Allergic Asthma: A type of asthma triggered by inhaled allergens, causing inflammation and narrowing of the airways.
  • Sickle Cell Disease (SCD): A genetic blood disorder where red blood cells become crescent-shaped, leading to blockages in small blood vessels and various complications.
  • Hematopoietic Cell Transplantation (HCT): A procedure where healthy blood-forming stem cells are transplanted to replace diseased or damaged bone marrow.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical and physiological effects.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Events (SAEs): Adverse events that result in death, are life-threatening, require hospitalization, cause persistent or significant disability, or lead to birth defects.
  • Urticaria Activity Score 7 (UAS7): A tool used to assess the severity of chronic urticaria, measuring the intensity of itch and number of hives over seven days.
  • Forced Expiratory Volume in 1 second (FEV1): A measure of lung function that represents the volume of air a person can forcefully exhale in one second.
  • Graft-versus-Host Disease (GVHD): A complication of stem cell transplantation where donor cells attack the recipient's tissues.

References

  1. https://clinicaltrials.gov/study/NCT06353971
  2. https://clinicaltrials.gov/study/NCT06162728
  3. https://clinicaltrials.gov/study/NCT06592768
  4. https://clinicaltrials.gov/study/NCT06145282